Savant Capital LLC Has $3.65 Million Stake in Incyte Co. (NASDAQ:INCY)

Savant Capital LLC boosted its holdings in shares of Incyte Co. (NASDAQ:INCYFree Report) by 304.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 52,792 shares of the biopharmaceutical company’s stock after acquiring an additional 39,749 shares during the quarter. Savant Capital LLC’s holdings in Incyte were worth $3,646,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of the business. Orion Portfolio Solutions LLC bought a new position in shares of Incyte during the 3rd quarter worth about $770,000. CWA Asset Management Group LLC bought a new position in Incyte during the fourth quarter worth about $1,933,000. Greenwood Capital Associates LLC bought a new position in Incyte during the third quarter worth about $433,000. Tri Ri Asset Management Corp acquired a new stake in Incyte during the third quarter valued at approximately $3,292,000. Finally, Cypress Capital Group bought a new stake in shares of Incyte in the 3rd quarter valued at approximately $971,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Incyte Trading Down 2.9 %

INCY stock opened at $66.33 on Wednesday. The company has a quick ratio of 1.82, a current ratio of 1.87 and a debt-to-equity ratio of 0.01. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a market cap of $12.78 billion, a P/E ratio of 473.82, a PEG ratio of 0.53 and a beta of 0.70. The business has a fifty day moving average of $71.69 and a 200-day moving average of $69.18.

Incyte (NASDAQ:INCYGet Free Report) last released its earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%. As a group, equities research analysts expect that Incyte Co. will post 0.35 EPS for the current year.

Insider Activity at Incyte

In related news, EVP Steven H. Stein sold 12,352 shares of Incyte stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the transaction, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This trade represents a 15.57 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Vijay K. Iyengar sold 6,043 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $75.38, for a total transaction of $455,521.34. Following the completion of the sale, the executive vice president now directly owns 30,658 shares of the company’s stock, valued at $2,311,000.04. The trade was a 16.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 19,695 shares of company stock worth $1,444,356 over the last ninety days. Company insiders own 17.60% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on INCY. JPMorgan Chase & Co. raised their target price on Incyte from $65.00 to $71.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group lifted their price objective on Incyte from $63.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. StockNews.com lowered shares of Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday. BMO Capital Markets reissued an “underperform” rating and set a $52.00 price target (up from $48.00) on shares of Incyte in a report on Wednesday, October 30th. Finally, Royal Bank of Canada reduced their price target on shares of Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Incyte has a consensus rating of “Hold” and a consensus price target of $75.59.

View Our Latest Report on INCY

Incyte Profile

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Featured Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.